Exicure to Present at Upcoming TIDES USA Oligonucleotide & Peptide Therapeutics Conference

Rhea-AI Summary

Exicure, Inc. (NASDAQ: XCUR) announced a poster presentation at TIDES USA 2022 from May 9-12, 2022. The presentation focuses on the development of spherical nucleic acids targeting SCN9A for treating neuropathic pain, with Poster Board Assignment Number 54. The poster will be available for both in-person and virtual viewing, accessible for two weeks post-conference. Exicure is pioneering nucleic acid therapies for neurological disorders and hair loss, working from its Chicago facility.

CHICAGO--(BUSINESS WIRE)-- Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced a poster presentation at TIDES USA 2022, May 9-12, 2022.

Poster presentation: “Development of Spherical Nucleic Acids Targeting SCN9A For the Treatment of Neuropathic Pain” – Poster Board Assignment Number: 54

Exicure will have the poster for viewing both in-person and virtually during the conference. Virtual posters will go live at the start of the conference and will be available to conference attendees for 2 weeks.

Exicure will add the poster to its website after the conference.

About Exicure

Exicure, Inc. is an early-stage biotechnology company developing nucleic acid therapies targeting ribonucleic acid against validated targets to neurological disorders and hair loss. The team includes a diverse scientific group with expertise in nucleic acid chemistry, drug development and neuroscience. Headquartered in Chicago, Illinois, the Company conducts its discovery and development efforts in-house with a dedicated 30,000 square foot facility, including rapid and automated high throughput nucleic acid synthesis and screening.

For further information, see www.exicuretx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220509005183/en/

Media:

Karen Sharma

MacDougall

781-235-3060

ksharma@macdougall.bio

Source: Exicure, Inc.

FAQ

What is Exicure presenting at TIDES USA 2022?

Exicure is presenting a poster on the 'Development of Spherical Nucleic Acids Targeting SCN9A for the Treatment of Neuropathic Pain'.

When is Exicure's presentation at TIDES USA 2022?

Exicure's poster presentation is scheduled for May 9-12, 2022.

Where can I view Exicure's poster presentation from TIDES USA 2022?

The poster will be available both in-person and virtually, accessible for two weeks after the conference.

What is the significance of the SCN9A target in Exicure's research?

SCN9A is a target for developing treatments for neuropathic pain, which Exicure is focusing on with its spherical nucleic acids.

What type of therapies is Exicure developing?

Exicure is developing nucleic acid therapies targeting RNA to address neurological disorders and hair loss.